Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year High – Time to Buy?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $16.73 and last traded at $16.66, with a volume of 1825247 shares changing hands. The stock had previously closed at $16.11.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AMRX shares. UBS Group assumed coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective on the stock. Zacks Research lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Truist Financial raised their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Weiss Ratings lowered Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.80.

Amneal Pharmaceuticals Price Performance

The firm has a market cap of $5.31 billion, a P/E ratio of 43.84 and a beta of 1.30. The stock has a 50 day moving average of $13.56 and a 200 day moving average of $13.29.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million for the quarter. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares in the company, valued at $1,211,960.40. The trade was a 27.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of AMRX. Kemnay Advisory Services Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at $26,000. Federated Hermes Inc. raised its position in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Comerica Bank lifted its stake in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares during the last quarter. Spire Wealth Management lifted its stake in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the last quarter. Finally, Transamerica Financial Advisors LLC boosted its position in Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after buying an additional 2,460 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.